Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)
Novo Nordisk tempers expectations for hefty M&A deals as diabetes, obesity sales soar
As Novo Nordisk counts a surge in sales, thanks in large part to its obesity and diabetes franchises, the Danish drugmaker has its checkbook out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
